TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

רוזן, משרד עורכי דין מוביל, מעודד את משקיעי Skye Bioscience, Inc לקבל ייעוץ משפטי לפני מועד מועד חשוב בתביעה ייצוגית בניירות ערך – SKYE

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Rosen Law Firm
רוזן, משרד עורכי דין מוביל, מעודד את משקיעי Skye Bioscience, Inc לקבל ייעוץ משפטי לפני מועד מועד חשוב בתביעה ייצוגית בניירות ערך – SKYE

Rosen Law Firm notifies Skye Bioscience investors of an upcoming class action lawsuit deadline on January 16, 2026, related to allegedly misleading statements about the company's clinical drug nimacimab and its potential effectiveness.

Insights
NEWTZ   positive

Company is expanding leadership, focusing on innovative financial solutions for small businesses, and positioning itself to redefine payment processing with advanced technology


SKYE   negative

The lawsuit alleges that the company made false and materially misleading statements about its business, operations, and future prospects, specifically regarding the clinical effectiveness of its drug nimacimab, which suggests potential corporate misconduct and investor deception